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Abstract
Background and objectives
Resolvin D1 (RvD1) is a specialized pro-resolving lipid mediator that has been previously
shown to attenuate vascular smooth muscle cell (VSMC) migration, a key process in the
development of intimal hyperplasia. We sought to investigate the role of the cAMP/PKA
pathway in mediating the effects of the aspirin-triggered epimer 17R-RvD1 (AT-RvD1) on
VSMC migration.
Methods
VSMCs were harvested from human saphenous veins. VSMCs were analyzed for intracellu-
lar cAMP levels and PKA activity after exposure to AT-RvD1. Platelet-derived growth factor
(PDGF)-induced migration and cytoskeletal changes in VSMCs were observed through
scratch, Transwell, and cell shape assays in the presence or absence of a PKA inhibitor
(Rp-8-Br-cAMP). Further investigation of the pathways involved in AT-RvD1 signaling was
performed by measuring Rac1 activity, vasodilator stimulated phosphoprotein (VASP) phos-
phorylation and paxillin translocation. Finally, we examined the role of RvD1 receptors
(GPR32 and ALX/FPR2) in AT-RvD1 induced effects on VSMC migration and PKA activity.
Results
Treatment with AT-RvD1 induced a significant increase in cAMP levels and PKA activity in
VSMCs at 5 minutes and 30 minutes, respectively. AT-RvD1 attenuated PDGF-induced
VSMC migration and cytoskeletal rearrangements. These effects were attenuated by the
PKA inhibitor Rp-8-Br-cAMP, suggesting cAMP/PKA involvement. Treatment of VSMC with
AT-RvD1 inhibited PDGF-stimulated Rac1 activity, increased VASP phosphorylation, and
attenuated paxillin localization to focal adhesions; these effects were negated by the addi-
tion of Rp-8-Br-cAMP. The effects of AT-RvD1 on VSMC migration and PKA activity were
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attenuated by blocking ALX/FPR2, suggesting an important role of this G-protein coupled
receptor.
Conclusions
Our results suggest that AT-RvD1 attenuates PDGF-induced VSMC migration via ALX/
FPR2 and cAMP/PKA. Interference with Rac1, VASP and paxillin function appear to medi-
ate the downstream effects of AT-RvD1 on VSMC migration.
Introduction
Peripheral artery disease (PAD) affects >200 million people globally, and it currently repre-
sents a major cause of morbidity as well as healthcare expenditures in the United States. Open
surgery and endovascular interventions are capable of improving circulation in PAD, but their
long-term efficacy is greatly diminished by excessive scarring of vessels (restenosis) which
occurs in approximately half of successfully treated patients [1–9]. Intimal hyperplasia (IH) is
a prototypic response to vascular injury that, when excessive, leads to restenosis [10,11]. Vas-
cular smooth muscle cells (VSMC) and their phenotypic alterations are central to the patho-
physiology of IH. VSMCs naturally reside in the tunica media; however, in response to
vascular injury they migrate into the tunica intima and proliferate, causing thickening of the
vessel wall and narrowing of the lumen [12,13]. Several physical and biological factors have
been characterized as promoters of VSMC migration, including blood pressure, sheer stress
and a vast array of cytokines and growth factors, such as the platelet-derived growth factor
(PDGF) [14–16].
Resolvins constitute a family of specialized pro-resolving mediators (SPMs) derived from
the omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA). Both D-series (derived from DHA) and E-series (derived from EPA) have been
shown to mediate active resolution of inflammation across a broad range of diseases (e.g. coli-
tis, lung injury, periodontitis, etc.), and have reached the stage of early clinical trials [17–19].
In prior studies, we identified a potential “resolution-deficit” in PAD patients [20], and have
shown that SPMs can modulate vascular injury responses [21–24]. Resolvin D1 (RvD1), like
other members of the D-series resolvins, has two different isoforms identified in biologic sam-
ples [25,26]: 17S-resolvin D1 (17S-RvD1) and the “aspirin-triggered” 17R-resolvin D1
(17R-RvD1 or AT-RvD1). The first reaction of resolvin D1 synthesis determines whether
DHA will eventually convert to the 17S or 17R isoform; 15-Lipoxygenase (15-LOX) is respon-
sible for the synthesis of 17S-RvD1, whereas Cyclooxygenase 2 (COX-2), after being covalently
modified by aspirin, promotes the synthesis of AT-RvD1. AT-RvD1 can also be produced
endogenously in the absence of aspirin by alternative pathways involving cytochrome P450
enzymes [17]. The “aspirin-triggered” versions of SPMs are of particular relevance because of
the ubiquitous use of aspirin for primary and secondary prevention in cardiovascular patients,
identification of these mediators in human blood following fish oil supplementation [26], and
their relative resistance to metabolic inactivation in comparison to the S-epimers [19,27]. Both
isoforms of RvD1 bind to two known G-protein coupled receptors (GPCR), GPR32 and ALX/
FPR2 [28].
In recent studies, RvD1, as well as other SPMs, was shown to attenuate VSMC migration in
vitro as well as IH in vivo in murine and rabbit models of arterial injury [21,22,24]. Little is
known about RvD1 signaling pathways, particularly in vascular cells. VSMC migration is a
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complex process involving an orchestrated concert of molecular events leading to actin poly-
merization, focal adhesion formation and cellular contraction [29]. Cyclic adenosine mono-
phosphate (cAMP) and its target protein kinase A (PKA) are key mediators of cell migration
in many cell types and have been extensively shown to be anti-motogenic and anti-inflamma-
tory in VSMCs [23,30–34]. Therefore, the cAMP/PKA pathway is highly relevant to investiga-
tions of VSMC migration. In this study we demonstrate that AT-RvD1 exerts anti-motogenic
effects on VSMCs via ALX/FPR2 and involving the cAMP/PKA pathway.
Materials and methods
Cell culture and reagents
Primary VSMCs were isolated from human great saphenous veins discarded at the time of
bypass operation under a University of California San Francisco Institutional Review Board-
approved protocol (UCSF Committee on Human Research- Number: 10–03395; the commit-
tee waived the need for informed consent) as described previously [35]. VSMCs were cultured
at 37˚C and 5% CO2 in low glucose Dulbecco’s modified Eagle’s medium (DMEM; HyClone
Laboratories, Logan, UT, USA) containing 10% FBS (Life Technologies, Grand Island, NY).
VSMCs between passages 2 and 5 were utilized for all experiments. AT-RvD1 (7S,8R,17R-tri-
hydroxy-4Z,9E,11E,13Z,15E19Z-docosahexaenoic acid), 17S-RvD1 (7S,8R,17S-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) were obtained from Cayman Chemical (Ann
Arbor, MI, USA). The anti-GPR32 antibody was purchased from GeneTex (Irvine, CA, USA)
and the anti-ALX antibody from Abcam (Cambridge, United Kingdom). PDGF-BB was pur-
chased from Sigma-Aldrich (St. Louis, MO, USA) and Rp-8-Br-cAMP from Enzo Life Sciences
(Farmingdale, NY, USA). Phorbol 12,13-dibutyrate (PDBu) was purchased from Biolog (Hay-
ward, CA, USA) and chelerythrine chloride from Sigma-Aldrich (St. Louis, MO, USA).
Cell migration
Migration was studied using both a scratch assay and a Transwell assay. For the scratch assay,
cells were grown to near-confluence in 24-well plates, then serum-starved overnight in
DMEM containing 0.1% FBS. A scratch was applied to the cell monolayer using a sterile 200μl
pipette tip, and cells were pre-treated with AT-RvD1 (10nM) or vehicle (ethanol) with or with-
out Rp-8-Br-cAMP (10μM), anti-GPR32 antibody (2μg/ml), anti-ALX antibody (2μg/ml),
PDBu (10nM) or Chelerythrine (10μM) for 30 minutes. PDGF-BB (10ng/ml) was then added
to the appropriate experimental groups, and initial photomicrographs were taken using a
phase-contrast microscope (EVOS xl core, AMG, Mill Creek, WA). After overnight incuba-
tion, a second set of images was obtained to measure VSMC migration over the scratched area.
The cell-free area for each well and time-point was measured using the software ImageJ (ver-
sion 1.48, NIH; http://imagej.nih.gov/ij/download.html); we calculated the mean percent
wound closure and the fold wound closure of each treatment group vs. the negative control
group.
For the Transwell assay, cells were serum-starved overnight in DMEM containing 0.1%
FBS. VSMC migration was assayed using 8μm-pore gelatin-coated Transwell inserts (Costar,
Corning, NY). After serum starvation cells were seeded on each insert (40,000 per upper well).
Cells were pre-treated with AT-RvD1 (10nM) or vehicle (ethanol) with or without Rp-8-Br-
cAMP (10μM) for 30 minutes. PDGF-BB (10ng/ml) was then added to the lower well of the
appropriate experimental groups and cells were allowed to incubate for 4 hours. After scraping
off the non-migrated cells from the upper aspect of the porous membrane with a cotton swab,
the migrated cells on the lower aspect were fixed in methanol, DAPI-stained, mounted on
slides and visualized under a fluorescence microscope (EVOS fl, AMG, Mill Creek, WA). Four
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images of pre-selected areas (kept consistent between groups) were taken with the same cam-
era settings for all treatment groups. After setting the same particle size threshold for all the
groups, particles were automatically counted in each picture using the software ImageJ. The
total of migrated cells for each sample was used to calculate the fold cell transmigration of each
treatment group vs. the negative control (vehicle) group.
cAMP measurement
Confluent VSMCs grown in 12-well plates were serum-starved overnight in DMEM contain-
ing 0.1% FBS. Cells were treated with AT-RvD1 (10nM) and harvested at different times using
a 0.1N HCl, 1% Triton X-100 lysis buffer. After spinning the lysates at 12,000g for 10 minutes
and collecting the supernatants, cAMP and total protein contents were measured via ELISA
(Enzo Life Sciences, Farmingdale, NY, USA) and BCA assay (Thermo Fisher Scientific, Wal-
tham, MA, USA), respectively, following the manufacturers’ protocols. cAMP concentrations
in the lysates were calculated from the absorbance readouts using a four-parameter logistic fit
and then normalized by total protein content.
PKA activity assay
Confluent VSMCs grown in 24-well plates were serum-starved overnight in DMEM contain-
ing 0.1% FBS. Cells were treated with only AT-RvD1 (10nM) with or without anti-GPR32 anti-
body (2μg/ml) and/or anti-ALX antibody (2μg/ml). PKA activity was analyzed in crude cell
lysates (2.5μg) following the protocol of a commercially available assay kit (Enzo Life Sciences,
Farmingdale, NY, USA).
Cell shape measurement
Cells were seeded on 8-well chamber slides at a density of 4,000–6,000 cells/well in DMEM
containing 10% FBS for 24 hours, then serum-starved overnight in DMEM containing 0.1%
FBS. Cells were pre-treated with AT-RvD1 (10nM) or vehicle (ethanol) with or without Rp-
8-Br-cAMP (10μM) for 2 hours, followed by the addition of PDGF-BB (10ng/ml) for 1 hour.
Cells were then fixed in 3.7% formaldehyde, permeabilized in 0.1% Triton X-100, stained with
Alexa Fluor 568 phalloidin and mounted with a DAPI-containing mounting medium (South-
ern Biotech, Birmingham, AL, USA). One wash with PBS was performed in-between steps.
Images (10x) from five pre-selected areas (consistent between groups) per well were taken
using a fluorescence microscope and camera (model BX51 and DP70, Olympus, Shinjuku,
Tokyo, Japan), and length to width ratios were measured for each cell (20 per well) using the
software ImageJ.
Rac1 activity assay
Cells were grown in 60mm dishes, and then serum starved for 24 hours. Cells were then
treated with PDGF-BB (10ng/ml) and harvested at different time points for the time-course
experiment. In other experiments, cells were pre-treated with AT-RvD1 (10nM) or vehicle
(ethanol), with or without Rp-8-Br-cAMP (10μM) for 30 minutes, followed by PDGF-BB
(10ng/ml) for 15 minutes, after which cells were lysed and immediately snap-frozen in liquid
nitrogen. Rac1-GTP and total protein content were then measured using the G-LISA Rac1
Activation Assay Kit (Cytoskeleton, Inc. Denver CO, USA) following the manufacturer’s
instructions. Samples were diluted in lysis buffer to normalize total protein concentrations
before Rac1-GTP measurement. Results were calculated from the absorbance readouts, and
are shown as fold change vs. the negative control.
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Western blotting (phospho-VASP detection)
Cells were grown to near-confluence in 60mm dishes, and than serum starved for 48 hours. In
a preliminary set of experiments, cells were treated with AT-RvD1 (10nM) and harvested at
different time points. In subsequent experiments cells were pre-treated with AT-RvD1 (10nM)
or vehicle (ethanol) with or without Rp-8-Br-cAMP (10μM) for 30 minutes, followed by
PDGF-BB (10ng/ml) treatment for 5 min. Cells were then lysed using CellLytic M lysis buffer
(Sigma-Aldrich, St. Louis, MO, USA) plus Halt Protease Inhibitor Cocktail (Thermo Fisher
Scientific, Waltham, MA, USA) and immediately snap-frozen in liquid nitrogen. After con-
stant agitation at 4˚C for 30min, samples were centrifuged at 12,000g for 20 minutes, and the
supernatants (whole cell extracts) were collected. Total protein concentration was assessed
using the BCA assay (Thermo Fisher Scientific, Waltham, MA, USA) and 30μl of each protein
sample was loaded on 4–12% gradient electrophoresis gels (Thermo Fisher Scientific, Wal-
tham, MA, USA) and run at 200V for 22 minutes. A protein wet transfer on PVDF membrane
was then performed at 4˚C (100V for 60 minutes) followed by blocking the membranes in 5%
non-fat dry-milk with Tris-Buffered Saline and Tween-20 (TBST) for 60 minutes. The mem-
branes were probed with anti-p-VASP Ser 157 (1:1000 dilution, Cell Signaling Technologies,
Danvers, MA, USA) and anti-β-Actin (Sigma-Aldrich, St. Louis, MO, USA) antibodies at 4˚C
overnight. The next day membranes were washed, probed with an HRP-conjugated antibody
(Santa Cruz Biotechnologies, Santa Cruz, CA, USA), and bands were visualized through
chemiluminescence using the WesternBright quantum kit (Advansta, Menlo Park, CA, USA).
Blots were visualized using the ChemiDoc MP system (Bio-Rad, Hercules, CA, USA) and
bands analyzed using the ImageLab (version 4.0, Bio-Rad, Hercules, CA, USA). Results are
shown as fold-changes vs. time 0 or negative control of band intensity ratios between p-VASP
and β-Actin.
Immunofluorescent staining (paxillin)
Cells were seeded in 4-well chamber slides, and then serum-starved overnight in DMEM con-
taining 0.1% FBS. A scratch assay was performed as described above. After cell migration
occurred overnight, cells were fixed with 3.7% formaldehyde, permeabilized with 0.5% Triton
X-100, blocked with 2% Bovine Serum Albumin + 0.3% Triton X-100, and incubated with
anti-paxillin primary antibody (1:50 dilution, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4˚C. After that, cells were incubated with Alexa Fluor 488 secondary anti-
body (Thermo Fisher Scientific, Waltham, MA, USA) at room temperature for 1 hour. Three
washes with PBS were performed in-between steps. Cells were then mounted with a DAPI-
containing mounting medium (Southern Biotech, Birmingham, AL, USA). Five images of pre-
selected areas at the edge of the scratch (kept consistent between groups) were taken with the
same camera settings for all treatment groups using a fluorescence microscope and camera
(model BX51 and DP70, Olympus, Shinjuku, Tokyo, Japan). After setting the same particle
size threshold for all the groups, particles were automatically counted within the cells in each
picture using the software ImageJ and normalized by the number of DAPI-stained nuclei in
the same picture. Results are shown as fold change vs. the negative control group.
Statistical analysis
Data is shown as mean ± standard error of mean (SEM). One-way Analysis of Variance
(ANOVA) was run first on all the treatments groups, followed by Sidak’s or Dunnett’s post hoc
tests for multiple comparisons. For all analyses, P = 0.05 was considered to be the threshold for
statistical significance.
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Results
AT-RvD1 and 17S-RvD1 attenuate PDGF-induced VSMC migration
We compared the effects of the two isomers of RvD1 (17S and 17R) on VSMC migration. In
the scratch assays, AT-RvD1 (0.01–100nM) significantly reduced VSMC migration across a
wound after stimulation with PDGF-BB (Fig 1A). We did not observe an obvious dose-depen-
dent response, but rather a trend of efficacy at the low nanomolar range (1–10nM). 17S-RvD1
also showed anti-migratory effects in the lower dose range with a statistically significant effect
at 0.01nM (P<0.01; Fig 1B).
AT-RvD1 activates the cAMP/PKA pathway in VSMCs
As the PKA pathway is known to play a critical role regulating VSMC migration, we sought to
investigate whether changes in cAMP levels and PKA activity could be induced by AT-RvD1.
We found that AT-RvD1 causes a rapid increase in cAMP levels in VSMCs, peaking at 5 min-
utes (P<0.01) and subsequently returning to baseline at 15 minutes (Fig 2A). We also observed
a significant increase in PKA activity induced by AT-RvD1 peaking at 30 minutes (P<0.01;
Fig 2B).
AT-RvD1 attenuates PDGF-induced VSMC migration through a cAMP/
PKA-dependent mechanism
To test a possible link between the AT-RvD1 anti-migratory effect and the cAMP/PKA path-
way, we performed the VSMC scratch and Transwell migration assays in the presence of
AT-RvD1 and the specific PKA inhibitor Rp-8-Br-cAMP. In the scratch assay, AT-RvD1 sig-
nificantly inhibited VSMC migration induced by PDGF (40% inhibition of migration;
P<0.0001) and this effect was markedly attenuated by inhibition of PKA (38% reversal of
AT-RvD1 effect; P<0.001), suggesting an involvement of the kinase in the mechanism of
action (Fig 3A & 3B). Significantly, in the Transwell assay we observed strong inhibition of
Fig 1. RvD1 epimers attenuate PDGF-induced migration in VSMCs. AT-RvD1 inhibits the VSMC migratory response induced by
PDGF-BB (10ng/ml) in a scratch assay within a dose range of 0.01–100nM (A, n = 3). 17S-RvD1 also showed a significant reduction
in VSMC migration at the lowest nanomolar dose (0.01nM; B, n = 3). **P<0.01 vs. positive control, ***P<0.001 vs. positive control,
****P<0.0001 vs. positive control.
https://doi.org/10.1371/journal.pone.0174936.g001
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PDGF-induced migration by AT-RvD1 treatment (498 average migrated cells vs. 170; 66%
inhibition of migration; P<0.05) and an almost complete reversal of this effect with inhibition
of PKA (170 average migrated cells vs. 486; 97% reversal of AT-RvD1 effect; P<0.05) (Fig 3C).
Activating or inhibiting PKC by using PDBu or Chelerythrine, respectively, did not change the
anti-migratory effect of AT-RvD1 in the scratch migration assay (S1 Fig); this finding suggests
that PKC does not mediate the effect of AT-RvD1 on VSMC migration.
AT-RvD1 attenuates PDGF-induced cytoskeletal rearrangements in
VSMCs via PKA activity
We then turned our attention towards downstream pathways to investigate potential mecha-
nisms of action. PDGF is known to rapidly increase VSMC length to width ratio through stress
fiber formation in the initiation of a migratory response. We found that AT-RvD1 reduced the
length to width ratio by 32% compared to PDGF-BB only (P<0.001) and that the inhibition of
PKA with Rp-8-Br-cAMP reversed this cytoskeletal effect (P<0.01; Fig 4).
AT-RvD1 interferes with PDGF-induced Rac1 activation via PKA
Actin polymerization dynamics are central to the cytoskeletal rearrangements that take place
during VSMC leading edge formation and migration. Rac1 is a crucial regulator of actin fila-
ment formation, and its activity is required to promote VSMC migration [36]. Since PDGF-BB
is known to activate Rac1, we investigated this key protein as a downstream target candidate of
AT-RvD1 signaling. As the active form of Rac1 (Rac1-GTP) is a labile entity and prone to
hydrolysis to its inactive form (Rac1-GDP), we conducted a preliminary time-course experi-
ment to characterize Rac1 activation dynamics in PDGF-stimulated human VSMCs. Rac1-
GTP levels increased rapidly and peaked around 5–15 minutes after PDGF-BB addition,
returning to baseline by 30 minutes (Fig 5A). Based on these results, we tested the effect of
AT-RvD1 (10nM) at 15 minutes after PDGF-BB stimulation. We found that AT-RvD1
decreased the active form of Rac1 (Rac1-GTP) in VSMCs by 50% compared to the positive
Fig 2. AT-RvD1 increases cAMP levels and PKA activity in VSMCs. AT-RvD1 (10nM) rapidly increases cAMP levels peaking at 5
minutes and returning to baseline at 15 minutes (A, n4). AT-RvD1 (10nM) also increases PKA activity in VSMC with peak levels
seen at 30 minutes (B, n = 3). **P<0.01 vs. time 0.
https://doi.org/10.1371/journal.pone.0174936.g002
AT-RvD1 attenuates PDGF-induced vascular smooth muscle cell migration via cAMP/PKA
PLOS ONE | https://doi.org/10.1371/journal.pone.0174936 March 31, 2017 7 / 20
control (PDGF-BB only; P<0.05), an effect that was abolished by PKA inhibition (P<0.05;
Fig 5B).
AT-RvD1 induces VASP phosphorylation via PKA
VASP is another crucial regulator of actin polymerization, which down-regulates actin fila-
ment formation in its phosphorylated form [37]. Since PKA is known to phosphorylate VASP
[30,37] we sought to investigate whether AT-RvD1 could be involved in this event. In two
independent experiments AT-RvD1 (10nM) increased VASP phosphorylation in VSMC, with
a maximal change at 30 minutes (Fig 6A). In the presence of PDGF-BB, VASP phosphoryla-
tion was also increased in AT-RvD1-treated cells when compared to the negative control and
Fig 3. AT-RvD1 attenuates PDGF-induced migration in VSMCs by the cAMP/PKA pathway. AT-RvD1 (10nM) attenuates
PDGF-induced migration in VSMC in a scratch assay and in a Transwell assay. The PKA specific inhibitor (Rp-8-Br-cAMP 10μM)
partially reverts the effect of AT-RvD1 on VSMC migration in the scratch assay (A & B, n = 3) and almost completely in the Transwell
assay (C, n = 3).
https://doi.org/10.1371/journal.pone.0174936.g003
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Fig 4. AT-RvD1 attenuates PDGF-induced cytoskeletal rearrangements in VSMCs via PKA. VSMCs were
stained using an actin-phalloidin staining (representative pictures are shown in panel A). PDGF-BB (10ng/ml)
caused a significant increase of VSMC length to width ratio which reflects pro-migratory cytoskeletal
rearrangements (P<0.05 vs. negative control). AT-RvD1 (10nM) reduced this effect by lowering the VSMC length to
width ratio below the value observed in the negative control. The PKA specific inhibitor (Rp-8-Br-cAMP 10μM)
reversed the effects of AT-RvD1. (B, n = 4). ***P<0.001 vs. positive control, ##P<0.01.
https://doi.org/10.1371/journal.pone.0174936.g004
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cells treated with PDGF-BB only (P<0.05). Cells treated with PDGF-BB only did not show sig-
nificant changes in VASP phosphorylation compared to negative control. As expected, inhibit-
ing PKA activity effectively abolished AT-RvD1 induction of VASP phosphorylation (P<0.01;
Fig 6B).
AT-RvD1 interferes with paxillin localization to focal adhesion via PKA
Focal adhesions act in concert with actin polymerization during migration, making their con-
tribution critical to cellular motility. Since paxillin is one of the most important constituents of
focal adhesion complexes and participates downstream of PDGF signaling, we tested the
effects of AT-RvD1 in modulating the intracellular localization of paxillin in migrating
VSMCs. We found that AT-RvD1 reduced paxillin localization in focal adhesions of migrating
VSMC in a scratch assay (Fig 7) compared to the positive control group (P<0.05). Further-
more, PKA inhibition reversed the effects of AT-RvD1 on paxillin localization (P<0.05).
AT-RvD1 modulates PKA activity and cell migration in VSMCs through
ALX/FPR2
RvD1 functions through at least two known G protein-coupled receptors, GPR32 and FPR2/
ALX; We observed that by blocking ALX/FPR2 we almost completely reversed AT-RvD1
effects on PDGF-stimulated migration (Fig 8A). Inhibition of ALX/FPR2 also completely abol-
ished AT-RvD1 induced up-regulation of PKA activity at 30 minutes (P<0.05), while after
blocking GPR32 we observed only a partial and not statistically significant reversal of the effect
(Fig 8B).
Fig 5. AT-RvD1 attenuates PDGF-induced Rac1 activation via PKA. PDGF-BB (10ng/ml) stimulation of VSMCs induces a rapid
Rac1 activation peaking at 5–15 minutes and dropping at 30 minutes (A; n = 1). AT-RvD1 (10nM) attenuates Rac1 activation induced
by PDGF-BB (10ng/ml) at 15 minutes; the effect of AT-RvD1 is abrogated by adding a PKA specific inhibitor (Rp-8-Br-cAMP 10μM)
(B; n4).
https://doi.org/10.1371/journal.pone.0174936.g005
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Fig 6. AT-RvD1 induces VASP phosphorylation via PKA. AT-RvD1 alone induced VASP phosphorylation
which peaked at 30 minutes as shown in a representative blot (A; n = 2). PDGF-BB alone did not change
VASP phosphorylation significantly vs. negative control. AT-RvD1 (10nM) induced VASP phosphorylation in
the presence of PDGF-BB as shown in a representative blot and quantification of three independent
experiments. The induction of phosphorylation was abolished by addition of a PKA specific inhibitor (Rp-8-Br-
cAMP 10μM)(B; n = 3). *P<0.05 vs. positive control, #P<0.05, ##P<0.01.
https://doi.org/10.1371/journal.pone.0174936.g006
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Fig 7. AT-RvD1 prevents paxillin localization to focal adhesions in PDGF-stimulated VSMCs. Total paxillin
was visualized in VSMCs using immunofluorescence (representative pictures are shown in panel A). By quantifying
the number of particles (normalized by cell number) we observed that PDGF-BB (10ng/ml) induced localization of
paxillin to focal adhesions at the leading edge of migrating VSMCs, while AT-RvD1 (10nM) attenuated this effect.
PKA inhibition (with Rp-8-Br-cAMP 10μM) reversed the AT-RvD1 effect significantly (B; n = 4). *P<0.05 vs. positive
control, #P<0.05.
https://doi.org/10.1371/journal.pone.0174936.g007
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Discussion and conclusions
VSMC migration is a critical feature of the prototypic response to vascular injury, and an
essential step in IH development and restenosis. Recent studies have demonstrated a range of
vasculo-protective properties of the DHA-derived SPM [21,22,24], including inhibition of
VSMC migration; however the underlying molecular mechanisms are unclear. 17R-RvD1 is
the aspirin-triggered isoform of RvD1, making it particularly of interest clinically as most
patients affected by atherosclerosis receive long-term aspirin treatment. In a recent report,
AT-RvD1 was detected by liquid chromatography–tandem mass spectrometry (LC-MS/MS)-
based metabololipidomics in human plasma from patients affected by coronary heart disease
treated with aspirin with and without an EPA and DHA supplement [26]. AT-RvD1 released
from a bio-degradable material has been recently shown to decrease neutrophil infiltration
and to increase the anti-inflammatory monocyte/macrophage population in a murine model
[38]. In another recent study, AT-RvD1 has been shown to suppress TGF-β-induced migration
and invasion of A549 lung cancer cells [39]. In the present study, we investigated possible
mechanisms through which AT-RvD1 exerts an anti-migratory effect in VSMCs. PDGF,
among other trophic factors and cytokines, is established as a potent migratory stimulus in
acute vascular injury. Our findings suggest that ALX/FPR2, via the second messenger cAMP
and its downstream target PKA, is involved in AT-RvD1 modulation of VSMC phenotype in
the presence of PDGF-BB. In addition, we demonstrate that AT-RvD1 signaling directly inter-
feres with key components of the actin polymerization machinery and focal adhesion forma-
tion in VSMCs, and that these effects are also dependent, at least in part, on the cAMP/PKA
pathway (Fig 9). Collectively, these findings add new insight into the mechanisms by which
RvD1 exerts direct effects on VSMC phenotype.
Fig 8. AT-RvD1 effects on VSMC migration and cAMP levels are mediated by ALX/FPR2. AT-RvD1 (10nM) reduced PDGF-BB-
induced (10ng/ml) VSMC migration in a scratch assay, and blocking ALX/FPR2 with a specific antibody (2μg/ml) neutralized this
effect whereas an anti-GPR32 specific antibody (2μg/ml) showed virtually no effect (A, n3). The AT-RvD1-induced increase in PKA
activity at 30 minutes is almost completely reversed by an anti-ALX/FPR2 specific antibody (2μg/ml) whereas an anti-GPR32 specific
antibody (2μg/ml) showed only a not statistically significant partial reversal (B; n = 6). ***P<0.001 vs. positive control, #P<0.05.
https://doi.org/10.1371/journal.pone.0174936.g008
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The mechanism of action of SPMs and particularly of resolvins remains greatly unexplored
in vascular cells, with most current knowledge based on studies in leukocytes and other non-
vascular cell types [40]. SPMs, like other locally acting autacoids, are likely to exert differential
cell- and context-dependent effects. In neutrophils, RvE1 attenuates TNF-α signaling through
Fig 9. Schematic of proposed pathway by which RvD1 modulates VSMC migration. The schematic shows a summary of our
findings in a proposed simplified mechanism for the effects of AT-RvD1 on VSMC migration. AT-RvD1 increases cAMP levels at least
by activating ALX/FPR2; the subsequent activation of PKA interferes with actin polymerization by inhibiting VASP (by phosphorylation)
and Rac1, and with focal adhesion formation by decreasing paxillin localization to the cell leading edge. “R” and “C” represent the
regulatory and the catalytic subunits of PKA, respectively.
https://doi.org/10.1371/journal.pone.0174936.g009
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ERK activation, and blocks cAMP production and NF-κB signaling by binding to its receptors
ChemR23 and BLT1, respectively [41]. In macrophages, RvD1 altered specific miRNAs
involved with resolution signaling, in a receptor-dependent fashion [42]. In lung cancer cells,
AT-RvD1 has been recently shown to attenuate TGF-β1-induced epithelial-to-mesenchymal
transition by inhibiting the mTOR pathway [39]. In this study, we report the involvement of
cAMP in mediating AT-RvD1 effects in VSMCs. Interestingly, cAMP has been recently shown
to be involved in RvD1 signaling in other cell types; in one study, RvD1 increased alveolar
fluid clearance by activating the Na, K-ATPase channel via the ALX/cAMP/PI3K pathway
[43], and in another study it was found to decrease MK2 phosphorylation via cAMP in bone
marrow-derived macrophages [44]. Although the cAMP pathway regulates a wide variety of
cellular functions, its role in cell motility is widely appreciated in multiple cell types [30].
cAMP has consistently emerged as an important negative regulator of VSMC migration, and
at least part of this activity appears as a consequence of interference with the PDGF signaling
pathway. For example, the β-adrenergic receptors are well known down-regulators of PDGF-
induced VSMC migration, and they act by elevating intracellular cAMP levels [45,46]. More-
over, a recent study showed that cAMP-phosphodiesterase 1C regulates VSMC growth, migra-
tion and IH, suggesting a protective role of cAMP in VSMC proliferation [47]. While the
present study did not examine proliferative pathways, we have previously demonstrated cyto-
static activity of D-series resolvins in VSMC in vitro and in vivo [21,24].
A recent study showed elevation of cAMP in murine macrophages by RvD1 [48], and our
prior studies with the DHA-derived SPM maresin-1 (Mar-1) showed a similar effect of
increasing intracellular cAMP in human VSMCs and endothelial cells [23]. In this study we
observed an acute, transient increase in cAMP levels in VSMCs following exposure to
AT-RvD1; by 15 minutes cAMP levels returned to baseline levels. Concurrently, we observed a
significant increase in PKA activity induced by AT-RvD1 30 minutes after administration that
was almost completely abolished by blocking ALX/FPR2. Our data demonstrates a link
between the cAMP/PKA pathway and the anti-migratory phenotypic and downstream signal-
ing in VSMC mediated by AT-RvD1.
In addition, we identified that some of the downstream targets of PKA known to be
involved in cell migration are altered by AT-RvD1 in a PKA-dependent fashion. Rac1 is a
small G-protein that has been characterized extensively as a critical regulator of the actin poly-
merization machinery [49,50]. Rac1 activity promotes the formation of actin filaments and
has been shown to be required for PDGF-induced fibroblast and VSMC migration [36].
Although PKA has been shown to interact with Rac1, the exact relationship between the two
proteins remain largely unknown and seem to vary considerably between different cell types
[30]. A recent study has shown that Exendin-4 (a glucagon-like protein-1 receptor agonist)
inhibits Rac1 activity through PKA in VSMCs which supports a negative regulation of actin
filament formation by cAMP in these cells [51]. In our study, Rac1 activation by PDGF was
significantly attenuated by AT-RvD1 in a PKA-dependent fashion. While the connection
between PKA and VASP is well characterized in VSMCs [30,32,37,45], the one between PKA
and Rac1 is complex and not well defined. For instance, PKA has been shown to directly phos-
phorylate Rac1 in neuronal cells and thus inhibit its activity [52]. In vitro, PKA also phosphor-
ylates and thus inactivates P-Rex1, a type of GEF (Guanine nucleotide Exchange Factor)
involved in the activation of Rac1 [53,54]. Interestingly, in a recent study, RvD1 was shown to
induce phagocytosis in macrophages by increasing Rac1 activation [55]. Given the importance
of actin polymerization in both phagocytosis and cell motility, and the homeostatic effects of
RvD1 on efferocytosis and migration, it is not surprising that RvD1 might demonstrate oppo-
site effects on Rac1 in different cell types and contexts.
AT-RvD1 attenuates PDGF-induced vascular smooth muscle cell migration via cAMP/PKA
PLOS ONE | https://doi.org/10.1371/journal.pone.0174936 March 31, 2017 15 / 20
VASP is a well-established target of PKA; via phosphorylation at serine 157, PKA dimin-
ishes the actin nucleating activity of VASP as well as its binding to actin filaments, thereby
inhibiting smooth muscle migration [30,37,45]. We observed an effect of AT-RvD1 on VASP
phosphorylation/inactivation, and this mechanism most likely inhibits migration independent
of the PDGF pathway since the growth factor alone did not induce significant changes in phos-
pho-VASP levels. The effects of AT-RvD1 on VASP were mediated via PKA, as Rp-8-br-
cAMP completely abolished the change. To our knowledge, this is the first evidence that links
AT-RvD1 to VASP phosphorylation through PKA. As shown by others, VASP phosphoryla-
tion via cAMP promoted endothelial barrier function [56]; since cAMP in general has an anti-
inflammatory role in endothelial cells, the observed protective effects of Mar-1 or RvD1 in ani-
mal models of acute lung injury [43,57] could be imparted through elevation of cAMP levels.
Interestingly in murine macrophages [48] and human endothelial cells (unpublished data
from our lab) RvD1 has been shown to increase intracellular cAMP levels. The extent of
involvement of VASP in mediating RvD1 actions under various migratory agonists remains to
be explored.
Paxillin, in response to motogenic stimuli such as PDGF-BB, localizes towards the leading
edges of the cell and functions as a scaffold for other proteins, including Src and FAK, to pro-
mote focal adhesion complex formation and thus migration [58]. Regulation of paxillin by
PKA remains unclear in VSMCs; however, PKA has been shown to prevent paxillin localiza-
tion in focal adhesions through disruption of its interactions with integrins in human leuko-
cytes [59]. Moreover, another study demonstrated cAMP to inhibit migration in pancreatic
adenocarcinoma cells, and PKA had a specific role in preventing paxillin accumulation in
focal adhesions within those cells [60]. We found that AT-RvD1 interfered with the PDGF
pathway by attenuating paxillin localization at the leading edge of migrating VSMCs, suggest-
ing decreased focal adhesion formation as an important mechanism by which AT-RvD1 can
regulate VSMC migration. Although AT-RvD1 effects on paxillin appeared PKA-dependent,
the intermediate effectors between PKA and paxillin remains to be explored. Of note, we were
unable to detect significant changes in paxillin phosphorylation levels by AT-RvD1 via immu-
nofluorescence in VSMCs (data not shown).
The molecular mechanisms underlying RvD1 signaling in vascular cells remain a subject
of ongoing investigation. Although the cAMP/PKA pathway appears to be involved in the
regulation of VSMC migration by AT-RvD1, it likely represents one component within a
more complex signaling cascade. We used two different migration assays to test for PKA
dependency of AT-RvD1 effects on VSMC migration. PKA inhibition almost completely
reversed the effects of AT-RvD1 on VSMC migration in the Transwell assay but less so in
the scratch assays; the partial reversal in the scratch assay suggests that other pathways likely
act in concert with the cAMP/PKA axis. Neither of the two migration assays measures
migration selectively, as cell adhesion and proliferation may also be involved in the mea-
sured responses. Since PKC has been shown to promote inhibition of VSMC migration [61]
we utilized a PKC activator and inhibitor in order to determine whether or not the anti-
migratory effect of AT-RvD1 could be in part ascribed to PKC in addition to PKA; our
results did not support an interaction between AT-RvD1 and the PKC pathway in this con-
text (S1 Fig). At the receptor level, we observed that ALX/FPR2 was associated with both
PKA activity as well as downstream anti-migratory phenotype induced by AT-RvD1 in
VSMC; GPR32, on the other hand, only partially inhibited the rise in PKA activity and had
minimal effect on migration. In prior studies we had observed a greater role of GPR32 com-
pared to ALX/FPR2 in mediating the anti-migratory effects of 17S-RvD1 [21]; this discrep-
ancy might suggest that the two isomers interact differently with these two receptors or
might be attributed to inherent limitations of the blocking antibodies. Knock-down or
AT-RvD1 attenuates PDGF-induced vascular smooth muscle cell migration via cAMP/PKA
PLOS ONE | https://doi.org/10.1371/journal.pone.0174936 March 31, 2017 16 / 20
overexpression studies might be useful to further delineate the role of GPR32 in AT-RvD1
signaling; however, these manipulations are not physiological, and are challenging to achieve
in primary cultured human VSMCs. Furthermore, it is not known how ALX/FPR2 or
GPR32 affects cAMP (e.g. via direct activation of adenylyl cyclase or indirectly via inhibition
of phosphodiesterases), making this a relevant area of future investigation.
In summary, we demonstrate that the cAMP/PKA pathway is involved in the anti-moto-
genic effects of AT-RvD1 in PDGF-stimulated VSMCs. The RvD1 receptor ALX/FPR2 is
strongly implicated in this pathway. AT-RvD1 exposure interferes with the actin polymeriza-
tion machinery and focal adhesion formation in VSMCs. As we have previously identified bio-
active SPMs and their receptors in the vessel wall [21] these findings provide potential insight
into the molecular mechanisms of resolution of acute vascular injury.
Supporting information
S1 Fig. PKC does not mediate AT-RvD1 anti-migratory action in VSMCs. AT-RvD1
(10nM), the PKC activator PDBu (10nM) and the PKC inhibitor Chelerythrine (10μM) did
not cause any significant change in migration compared to negative control. As expected,
AT-RvD1 significantly attenuated PDGF-induced VSMC migration; however, the addition
of PDBu and Chelerythrine did not change AT-RvD1. PDBu alone did show a reduction in
PDGF-induced migration, but the change was not statistically significant. Chelerythrine
alone had no significant effect on PDGF-induced migration (n = 3). P<0.05 vs. positive
control.
(TIF)
S1 File. Data set of the study. The spreadsheet contains all data underlying the findings
described in this article.
(XLSX)
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